Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis

M. Lazarova, D. Lazar, F. Malek, J. Vaclavik, M. Taborsky, A. Ignaszewski

. 2019 ; 163 (4) : 318-323. [pub] 20181005

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20010322

BACKGROUND AND AIMS: The prognosis of patients with heart failure (HF) is still generally unfavorable. HF with reduced ejection fraction (HFrEF) patients reach target medication doses in very low percentages in daily clinical practice. HF disease management programs (DMP), including nurse and telemedicine support that facilitate achieving target medication doses, may improve the unfavorable prognosis. METHODS: We retrospectively analyzed the data of 738 patients with HFrEF who were followed in a single HF center during the years 1975-2011, for 6.4 (median) years. DMP, nurse and telemedicine support is established at this center. RESULTS: The group achieved left ventricle (LV) recovery after the HF treatment. The median LV ejection fraction improved from 25.0% at baseline to 50.0% at the time of the latest data collection. The proportion of NYHA II, III and IV classes decreased from 27.6%, 30.2% and 29.7% to 26.6%, 7.2% and 0.1%, respectively while the proportion of NYHA class I increased from 12.5% to 66.1%. Median NT-proBNP decreased from 975.0 to 324.0 pg/mL. The survival of the patient group was favorable; 79.7% survived 18.1 years after diagnosis of HF. A high percentage of the patients received recommended target or higher than target doses of angiotensin-converting enzyme inhibitors (82.0%) and beta-blockers (78.1%). CONCLUSION: The established pharmacotherapy resulted from an effective DMP and this contributed to the favorable prognosis.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20010322
003      
CZ-PrNML
005      
20200720150807.0
007      
ta
008      
200707s2019 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2018.059 $2 doi
035    __
$a (PubMed)30305762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Lazárová, Marie $7 xx0074090 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
245    10
$a Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis / $c M. Lazarova, D. Lazar, F. Malek, J. Vaclavik, M. Taborsky, A. Ignaszewski
504    __
$a Literatura
520    9_
$a BACKGROUND AND AIMS: The prognosis of patients with heart failure (HF) is still generally unfavorable. HF with reduced ejection fraction (HFrEF) patients reach target medication doses in very low percentages in daily clinical practice. HF disease management programs (DMP), including nurse and telemedicine support that facilitate achieving target medication doses, may improve the unfavorable prognosis. METHODS: We retrospectively analyzed the data of 738 patients with HFrEF who were followed in a single HF center during the years 1975-2011, for 6.4 (median) years. DMP, nurse and telemedicine support is established at this center. RESULTS: The group achieved left ventricle (LV) recovery after the HF treatment. The median LV ejection fraction improved from 25.0% at baseline to 50.0% at the time of the latest data collection. The proportion of NYHA II, III and IV classes decreased from 27.6%, 30.2% and 29.7% to 26.6%, 7.2% and 0.1%, respectively while the proportion of NYHA class I increased from 12.5% to 66.1%. Median NT-proBNP decreased from 975.0 to 324.0 pg/mL. The survival of the patient group was favorable; 79.7% survived 18.1 years after diagnosis of HF. A high percentage of the patients received recommended target or higher than target doses of angiotensin-converting enzyme inhibitors (82.0%) and beta-blockers (78.1%). CONCLUSION: The established pharmacotherapy resulted from an effective DMP and this contributed to the favorable prognosis.
650    _2
$a beta blokátory $x terapeutické užití $7 D000319
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory ACE $x terapeutické užití $7 D000806
650    _2
$a management nemoci $7 D019468
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x farmakoterapie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a funkce levé komory srdeční $x účinky léků $7 D016277
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lazár, Dušan $7 xx0250171 $u Department of Biophysics, Faculty of Science, Palacky University Olomouc, Czech Republic
700    1_
$a Málek, Filip, $d 1966- $7 xx0105488 $u Heart Failure Centre, Hospital Na Homolce, Prague, Czech Republic
700    1_
$a Václavík, Jan $7 xx0169228 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
700    1_
$a Táborský, Miloš, $d 1962- $7 jn20010310074 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
700    1_
$a Ignaszewski, Andrew $u Department of Cardiology, Heart Function Clinics, St. Paul´s Hospital, Vancouver, Canada
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 163, č. 4 (2019), s. 318-323
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30305762 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20200707 $b ABA008
991    __
$a 20200717103623 $b ABA008
999    __
$a ok $b bmc $g 1545963 $s 1100414
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 163 $c 4 $d 318-323 $e 20181005 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20200707

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace